Validated Pipeline Across Major Neurodegenerative Diseases
Linkage Therapeutics is building a high-value therapeutic pipeline grounded in validated disease biology, with preclinical programs designed to address the underlying causes of neurodegeneration across multiple indications, including:
- Huntington’s disease, targeting mutant huntingtin (mHTT) with selective intrabodies that reduce toxic aggregation and restore proteostasis
- Alzheimer’s disease, demonstrating intrabody-mediated reduction of tau pathology and improved cell survival in human brain organoid models
- Parkinson’s disease, achieving potent reduction of α-synuclein aggregates, preservation of dopaminergic neurons, and improved functional outcomes in vivo
These programs are supported by externally validated data, robust preclinical in vivo models, and a clear path toward IND-enabling development.
